RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Suzhou’s Innovent Biologics climbed 19% higher in its first day of trading on the Hong Kong Exchange, following its IPO last week. The positive reception is the first time investors have driven one of Hong Kong’s pre-revenue biopharma IPOs higher in open market trading. Although the anticipation for the pre-revenue channel was very high, the previous three listings closed their first sessions more of less unchanged — and then moved lower in subsequent days, causing investors to wonder if Hong Kong’s channel for young biopharmas is a viable vehicle. Innovent’s performance creates hope that it is.
Source: China Biotoday
